Compounded semaglutide ban The FDA peptides news today 2025 landscape is characterized by significant regulatory activity, particularly concerning GLP-1 receptor agonists and compounded peptides. As of 2025, the Food and Drug Administration (FDA) has been actively clarifying policies, addressing shortages, and increasing enforcement on the manufacturing and distribution of these substances.FDA Type C meeting supports phase 2b/3 pathway for ... This period marks a crucial juncture for the peptide industry, with new rules reshaping its trajectory and impacting both approved medications and compounded formulations.2025年1月10日—FDAReopening Comment Period on Immunogenicity Risk of Host Cell Proteins in Follow-on RecombinantPeptideProducts.
A major focus for the FDA in 2025 has been the regulation of GLP-1 medications like semaglutide, following determinations that shortages of these injection products have been resolved. Concurrently, the agency has ramped up enforcement on compounding practices involving GLP-1s and other peptides. This includes issuing warning letters to entities like Pinnacle Professional Research dba Pinnacle Peptides and targeting facilities operating under 503A and 503B designationsFDA Decisions Expected: October 2025. The FDA's stance aims to ensure product safety and efficacy, particularly when it comes to custom peptide medications prepared by compounding pharmacies, even for individual patient prescriptions2025年7月21日—Icotrokinra is a first-in-class investigational targeted oralpeptidethat selectively blocks the IL-23 receptor.
Despite regulatory scrutiny on compounding, 2025 has also seen positive developments in FDA approvals for peptide-based therapiesFat Loss Peptides in 2025: Real Stories, Side Effects, and .... The agency approved a significant number of novel drugs, with peptides and oligonucleotides (TIDEs) representing a growing segment of these approvals. For instance, the FDA granted accelerated approval to Forzinity, a tetra-peptide for injection, and recognized the increasing value of peptide-based therapeutics, with over 80 FDA-approved drugs already on the market and more in development. Semaglutide itself has seen expanded indications, including for patients with type 2 diabetes.
Understanding the current FDA compliance status for various peptide compounds is essential for both consumers and industry professionals.One of the first FDA actions in 2025 wasexpanding semaglutide (Ozempic; Novo Nordisk) indicationsto include patients with type 2 diabetes and ... While the FDA has approved numerous peptides for therapeutic use, including insulin and human growth hormone, the regulatory landscape for compounded peptides is more complexNew FDA Rules Are Reshaping the Peptide Industry. The FDA has identified potential significant safety risks associated with certain bulk drug substances used in compounding. Consequently, guidance on what peptides can be compounded often hinges on whether they are FDA-approved, have GRAS (Generally Recognized as Safe) status, or possess a USP monograph. The agency's efforts to establish a "green list" import alert aim to protect Americans from unapproved and misbranded peptide drug products, such as those observed with semaglutide and tirzepatide from certain online vendors.
The peptide industry is experiencing rapid evolution, driven by advancements in drug development and increasing patient demand.In2025, theFDAapproved 46 novel drugs, including four TIDEs (onepeptide, three oligonucleotides, and one antibody drug conjugate containingpeptideas a ... The FDA's policy shifts in 2025 are reshaping the manufacturing landscape, emphasizing transparency and tightening controls. Future developments may include further clarification on product-specific guidances for generic peptide drug development and ongoing evaluation of immunogenicity risks for recombinant peptide products2026年1月14日—This web page provides information related to upcoming new and revised product-specific guidances (PSGs) to support the development and approval of safe and .... As the FDA continues to expand its oversight, particularly concerning 'Research Use Only' (RUO) labeling, the industry must adapt to a more stringent regulatory environment, ensuring that therapeutic peptides meet rigorous safety and efficacy standards.
Join the newsletter to receive news, updates, new products and freebies in your inbox.